BACKGROUND: Impaired or reduced CD3 zeta chain (CD3-zeta) expression in T cells has been identified in various cancers and may be associated with an ineffective immune response. The clinical significance of CD3-zeta chain expression in tumor-infiltrating lymphocytes (TILs) in gastric carcinoma remains unclear. METHODS: The authors immunohistochemically investigated CD3-zeta expression in TILs in 185 patients who had undergone curative gastrectomy. CD3-zeta/CD3 epsilon (CD3-epsilon) ratios were calculated. Patients were divided into two groups: a normal CD3-zeta group (n = 121) and a reduced CD3-zeta group (n = 64). Patients with a zeta per epsilon ratio of greater than 66% were placed in the normal CD3-zeta group. RESULTS: Patients in the normal CD3-zeta group had fewer lymph node metastasis (P < 0.01) and a shallower depth of invasion (P < 0.05) than those in the reduced CD3-zeta group. The 5-year survival rate was 72% in the normal CD3-zeta group, which was significantly better than that in the reduced CD3-zeta group (55%; P < 0.01). When stratified according to clinical stage, the prognostic value was significantly different only in Stage IV patients. Multivariate analysis showed that CD3-zeta expression was an independent prognostic factor (P = 0.03) next to depth of invasion and lymph node involvement. CONCLUSIONS: Reduced CD3-zeta expression in TILs was strongly correlated with progressive disease in gastric carcinomas. CD3-zeta expression in TILs is considered an immunologic, independent prognostic marker in gastric carcinoma patients. CD3-zeta normalization with cytokine treatment may lead to prolonged survival in advanced gastric carcinoma patients. Copyright 2002 American Cancer Society.
BACKGROUND: Impaired or reduced CD3 zeta chain (CD3-zeta) expression in T cells has been identified in various cancers and may be associated with an ineffective immune response. The clinical significance of CD3-zeta chain expression in tumor-infiltrating lymphocytes (TILs) in gastric carcinoma remains unclear. METHODS: The authors immunohistochemically investigated CD3-zeta expression in TILs in 185 patients who had undergone curative gastrectomy. CD3-zeta/CD3 epsilon (CD3-epsilon) ratios were calculated. Patients were divided into two groups: a normal CD3-zeta group (n = 121) and a reduced CD3-zeta group (n = 64). Patients with a zeta per epsilon ratio of greater than 66% were placed in the normal CD3-zeta group. RESULTS:Patients in the normal CD3-zeta group had fewer lymph node metastasis (P < 0.01) and a shallower depth of invasion (P < 0.05) than those in the reduced CD3-zeta group. The 5-year survival rate was 72% in the normal CD3-zeta group, which was significantly better than that in the reduced CD3-zeta group (55%; P < 0.01). When stratified according to clinical stage, the prognostic value was significantly different only in Stage IV patients. Multivariate analysis showed that CD3-zeta expression was an independent prognostic factor (P = 0.03) next to depth of invasion and lymph node involvement. CONCLUSIONS: Reduced CD3-zeta expression in TILs was strongly correlated with progressive disease in gastric carcinomas. CD3-zeta expression in TILs is considered an immunologic, independent prognostic marker in gastric carcinomapatients. CD3-zeta normalization with cytokine treatment may lead to prolonged survival in advanced gastric carcinomapatients. Copyright 2002 American Cancer Society.
Authors: Christiane Meyer; Alexandra Sevko; Marcel Ramacher; Alexandr V Bazhin; Christine S Falk; Wolfram Osen; Ivan Borrello; Masashi Kato; Dirk Schadendorf; Michal Baniyash; Viktor Umansky Journal: Proc Natl Acad Sci U S A Date: 2011-10-03 Impact factor: 11.205
Authors: Asif A Dar; Trupti N Pradhan; Dakshayni P Kulkarni; Sagar U Shah; Kanury V Rao; Devendra A Chaukar; Anil K D'Cruz; Shubhada V Chiplunkar Journal: Immunology Date: 2015-12-27 Impact factor: 7.397
Authors: Leticia Llanes-Fernández; Maria del Carmen Arango-Prado; Juan Manuel Alcocer-González; Marta Elena Guerra-Yi; Sonia Franco-Odio; Rolando Camacho-Rodríguez; Vicente Madrid-Marina; Reyes Tamez-Guerra; Cristina Rodríguez-Padilla Journal: J Cancer Res Clin Oncol Date: 2008-07-24 Impact factor: 4.553
Authors: Kristen M Drescher; Poonam Sharma; Patrice Watson; Zoran Gatalica; Stephen N Thibodeau; Henry T Lynch Journal: Fam Cancer Date: 2009-01-23 Impact factor: 2.375
Authors: Ivy Zortéa S Parise; Guilherme A Parise; Lúcia Noronha; Mirvat Surakhy; Thiago Demetrius Woiski; Denise B Silva; Tatiana Ei-Jaick B Costa; Maria Helena C P Del-Valle; Heloisa Komechen; Roberto Rosati; Melyssa Grignet Ribeiro; Marilza Leal Nascimento; José Antônio de Souza; Diancarlos P Andrade; Mariana M Paraizo; Marjorana Martini R Galvão; José Renato S Barbosa; Miriam Lacerda Barbosa; Gislaine C Custódio; Mirna M O Figueiredo; Ana Luiza M R Fabro; Gareth Bond; Marco Volante; Enzo Lalli; Bonald C Figueiredo Journal: Cancers (Basel) Date: 2019-11-05 Impact factor: 6.639